AU729966B2 - Pharmaceutical aerosol composition - Google Patents
Pharmaceutical aerosol composition Download PDFInfo
- Publication number
- AU729966B2 AU729966B2 AU86262/98A AU8626298A AU729966B2 AU 729966 B2 AU729966 B2 AU 729966B2 AU 86262/98 A AU86262/98 A AU 86262/98A AU 8626298 A AU8626298 A AU 8626298A AU 729966 B2 AU729966 B2 AU 729966B2
- Authority
- AU
- Australia
- Prior art keywords
- composition
- mmad
- aerosol
- low volatility
- hfa
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 239000000203 mixture Substances 0.000 title claims description 148
- 239000008249 pharmaceutical aerosol Substances 0.000 title description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Natural products CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 129
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 101
- 239000000443 aerosol Substances 0.000 claims description 73
- 239000002245 particle Substances 0.000 claims description 68
- 239000003380 propellant Substances 0.000 claims description 43
- KUVIULQEHSCUHY-XYWKZLDCSA-N Beclometasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(Cl)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)COC(=O)CC)(OC(=O)CC)[C@@]1(C)C[C@@H]2O KUVIULQEHSCUHY-XYWKZLDCSA-N 0.000 claims description 38
- 150000005828 hydrofluoroalkanes Chemical class 0.000 claims description 34
- LVGUZGTVOIAKKC-UHFFFAOYSA-N 1,1,1,2-tetrafluoroethane Chemical compound FCC(F)(F)F LVGUZGTVOIAKKC-UHFFFAOYSA-N 0.000 claims description 32
- 239000011149 active material Substances 0.000 claims description 24
- 239000006184 cosolvent Substances 0.000 claims description 24
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims description 20
- WRIDQFICGBMAFQ-UHFFFAOYSA-N (E)-8-Octadecenoic acid Natural products CCCCCCCCCC=CCCCCCCC(O)=O WRIDQFICGBMAFQ-UHFFFAOYSA-N 0.000 claims description 19
- LQJBNNIYVWPHFW-UHFFFAOYSA-N 20:1omega9c fatty acid Natural products CCCCCCCCCCC=CCCCCCCCC(O)=O LQJBNNIYVWPHFW-UHFFFAOYSA-N 0.000 claims description 19
- QSBYPNXLFMSGKH-UHFFFAOYSA-N 9-Heptadecensaeure Natural products CCCCCCCC=CCCCCCCCC(O)=O QSBYPNXLFMSGKH-UHFFFAOYSA-N 0.000 claims description 19
- 239000005642 Oleic acid Substances 0.000 claims description 19
- ZQPPMHVWECSIRJ-UHFFFAOYSA-N Oleic acid Natural products CCCCCCCCC=CCCCCCCCC(O)=O ZQPPMHVWECSIRJ-UHFFFAOYSA-N 0.000 claims description 19
- QXJSBBXBKPUZAA-UHFFFAOYSA-N isooleic acid Natural products CCCCCCCC=CCCCCCCCCC(O)=O QXJSBBXBKPUZAA-UHFFFAOYSA-N 0.000 claims description 19
- 238000000034 method Methods 0.000 claims description 13
- YFMFNYKEUDLDTL-UHFFFAOYSA-N 1,1,1,2,3,3,3-heptafluoropropane Chemical compound FC(F)(F)C(F)C(F)(F)F YFMFNYKEUDLDTL-UHFFFAOYSA-N 0.000 claims description 9
- 229950000210 beclometasone dipropionate Drugs 0.000 claims description 5
- 125000003158 alcohol group Chemical group 0.000 claims description 2
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 claims 10
- WGCNASOHLSPBMP-UHFFFAOYSA-N hydroxyacetaldehyde Natural products OCC=O WGCNASOHLSPBMP-UHFFFAOYSA-N 0.000 claims 5
- 235000019441 ethanol Nutrition 0.000 claims 2
- 125000005909 ethyl alcohol group Chemical group 0.000 claims 1
- 238000009472 formulation Methods 0.000 description 76
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 36
- 235000011187 glycerol Nutrition 0.000 description 29
- 230000008021 deposition Effects 0.000 description 10
- 229960001361 ipratropium bromide Drugs 0.000 description 10
- 230000010076 replication Effects 0.000 description 10
- 239000010419 fine particle Substances 0.000 description 9
- KEWHKYJURDBRMN-ZEODDXGYSA-M ipratropium bromide hydrate Chemical compound O.[Br-].O([C@H]1C[C@H]2CC[C@@H](C1)[N@@+]2(C)C(C)C)C(=O)C(CO)C1=CC=CC=C1 KEWHKYJURDBRMN-ZEODDXGYSA-M 0.000 description 9
- 239000000463 material Substances 0.000 description 9
- 239000004094 surface-active agent Substances 0.000 description 9
- 239000000725 suspension Substances 0.000 description 9
- 229940079593 drug Drugs 0.000 description 8
- 239000003814 drug Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 210000004072 lung Anatomy 0.000 description 7
- 239000000654 additive Substances 0.000 description 6
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 6
- 229960002052 salbutamol Drugs 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- 239000002202 Polyethylene glycol Substances 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 239000004615 ingredient Substances 0.000 description 5
- 229920001223 polyethylene glycol Polymers 0.000 description 5
- 230000000996 additive effect Effects 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- MWKFXSUHUHTGQN-UHFFFAOYSA-N decan-1-ol Chemical compound CCCCCCCCCCO MWKFXSUHUHTGQN-UHFFFAOYSA-N 0.000 description 4
- 239000002270 dispersing agent Substances 0.000 description 4
- 239000006199 nebulizer Substances 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 230000009885 systemic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- NOOLISFMXDJSKH-UTLUCORTSA-N (+)-Neomenthol Chemical compound CC(C)[C@@H]1CC[C@@H](C)C[C@@H]1O NOOLISFMXDJSKH-UTLUCORTSA-N 0.000 description 3
- NOOLISFMXDJSKH-UHFFFAOYSA-N DL-menthol Natural products CC(C)C1CCC(C)CC1O NOOLISFMXDJSKH-UHFFFAOYSA-N 0.000 description 3
- CBENFWSGALASAD-UHFFFAOYSA-N Ozone Chemical compound [O-][O+]=O CBENFWSGALASAD-UHFFFAOYSA-N 0.000 description 3
- 239000004480 active ingredient Substances 0.000 description 3
- 239000000556 agonist Substances 0.000 description 3
- -1 anti-leukotrienes Substances 0.000 description 3
- PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 description 3
- 235000019404 dichlorodifluoromethane Nutrition 0.000 description 3
- 238000009792 diffusion process Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 239000012530 fluid Substances 0.000 description 3
- 229960000676 flunisolide Drugs 0.000 description 3
- 230000005484 gravity Effects 0.000 description 3
- 229940041616 menthol Drugs 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- MIXMJCQRHVAJIO-TZHJZOAOSA-N qk4dys664x Chemical compound O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O.C1([C@@H](F)C2)=CC(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2C[C@H]3OC(C)(C)O[C@@]3(C(=O)CO)[C@@]2(C)C[C@@H]1O MIXMJCQRHVAJIO-TZHJZOAOSA-N 0.000 description 3
- 210000002345 respiratory system Anatomy 0.000 description 3
- 238000004062 sedimentation Methods 0.000 description 3
- CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 2
- HZAXFHJVJLSVMW-UHFFFAOYSA-N 2-Aminoethan-1-ol Chemical compound NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 2
- LCGLNKUTAGEVQW-UHFFFAOYSA-N Dimethyl ether Chemical compound COC LCGLNKUTAGEVQW-UHFFFAOYSA-N 0.000 description 2
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 2
- 229920002594 Polyethylene Glycol 8000 Polymers 0.000 description 2
- ATUOYWHBWRKTHZ-UHFFFAOYSA-N Propane Chemical compound CCC ATUOYWHBWRKTHZ-UHFFFAOYSA-N 0.000 description 2
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 239000000460 chlorine Substances 0.000 description 2
- 229910052801 chlorine Inorganic materials 0.000 description 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
- 230000001186 cumulative effect Effects 0.000 description 2
- 238000006073 displacement reaction Methods 0.000 description 2
- SNRUBQQJIBEYMU-UHFFFAOYSA-N dodecane Chemical compound CCCCCCCCCCCC SNRUBQQJIBEYMU-UHFFFAOYSA-N 0.000 description 2
- POULHZVOKOAJMA-UHFFFAOYSA-N dodecanoic acid Chemical compound CCCCCCCCCCCC(O)=O POULHZVOKOAJMA-UHFFFAOYSA-N 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 150000002334 glycols Chemical class 0.000 description 2
- NNPPMTNAJDCUHE-UHFFFAOYSA-N isobutane Chemical compound CC(C)C NNPPMTNAJDCUHE-UHFFFAOYSA-N 0.000 description 2
- XMGQYMWWDOXHJM-UHFFFAOYSA-N limonene Chemical compound CC(=C)C1CCC(C)=CC1 XMGQYMWWDOXHJM-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- RZJRJXONCZWCBN-UHFFFAOYSA-N octadecane Chemical compound CCCCCCCCCCCCCCCCCC RZJRJXONCZWCBN-UHFFFAOYSA-N 0.000 description 2
- 210000003300 oropharynx Anatomy 0.000 description 2
- 230000035515 penetration Effects 0.000 description 2
- OJTDGPLHRSZIAV-UHFFFAOYSA-N propane-1,2-diol Chemical compound CC(O)CO.CC(O)CO OJTDGPLHRSZIAV-UHFFFAOYSA-N 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- NPNPZTNLOVBDOC-UHFFFAOYSA-N 1,1-difluoroethane Chemical compound CC(F)F NPNPZTNLOVBDOC-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-UHFFFAOYSA-N 1,8-cineole Natural products C1CC2CCC1(C)OC2(C)C WEEGYLXZBRQIMU-UHFFFAOYSA-N 0.000 description 1
- TWJNQYPJQDRXPH-UHFFFAOYSA-N 2-cyanobenzohydrazide Chemical compound NNC(=O)C1=CC=CC=C1C#N TWJNQYPJQDRXPH-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 108010011485 Aspartame Proteins 0.000 description 1
- 208000027775 Bronchopulmonary disease Diseases 0.000 description 1
- 230000005653 Brownian motion process Effects 0.000 description 1
- 239000004255 Butylated hydroxyanisole Substances 0.000 description 1
- 239000004322 Butylated hydroxytoluene Substances 0.000 description 1
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 229920002307 Dextran Polymers 0.000 description 1
- 239000001856 Ethyl cellulose Substances 0.000 description 1
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 1
- WEEGYLXZBRQIMU-WAAGHKOSSA-N Eucalyptol Chemical compound C1C[C@H]2CC[C@]1(C)OC2(C)C WEEGYLXZBRQIMU-WAAGHKOSSA-N 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- QAQJMLQRFWZOBN-LAUBAEHRSA-N L-ascorbyl-6-palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](O)[C@H]1OC(=O)C(O)=C1O QAQJMLQRFWZOBN-LAUBAEHRSA-N 0.000 description 1
- 239000011786 L-ascorbyl-6-palmitate Substances 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 239000005639 Lauric acid Substances 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 235000021360 Myristic acid Nutrition 0.000 description 1
- TUNFSRHWOTWDNC-UHFFFAOYSA-N Myristic acid Natural products CCCCCCCCCCCCCC(O)=O TUNFSRHWOTWDNC-UHFFFAOYSA-N 0.000 description 1
- 208000007027 Oral Candidiasis Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 239000001089 [(2R)-oxolan-2-yl]methanol Substances 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 238000012387 aerosolization Methods 0.000 description 1
- 150000001335 aliphatic alkanes Chemical class 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001078 anti-cholinergic effect Effects 0.000 description 1
- 230000002590 anti-leukotriene effect Effects 0.000 description 1
- 239000000043 antiallergic agent Substances 0.000 description 1
- 229940065524 anticholinergics inhalants for obstructive airway diseases Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000010385 ascorbyl palmitate Nutrition 0.000 description 1
- 239000000605 aspartame Substances 0.000 description 1
- 235000010357 aspartame Nutrition 0.000 description 1
- IAOZJIPTCAWIRG-QWRGUYRKSA-N aspartame Chemical compound OC(=O)C[C@H](N)C(=O)N[C@H](C(=O)OC)CC1=CC=CC=C1 IAOZJIPTCAWIRG-QWRGUYRKSA-N 0.000 description 1
- 229960003438 aspartame Drugs 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000008468 bone growth Effects 0.000 description 1
- 230000004097 bone metabolism Effects 0.000 description 1
- 229940124630 bronchodilator Drugs 0.000 description 1
- 239000000168 bronchodilator agent Substances 0.000 description 1
- 238000005537 brownian motion Methods 0.000 description 1
- 235000019282 butylated hydroxyanisole Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940043253 butylated hydroxyanisole Drugs 0.000 description 1
- 235000010354 butylated hydroxytoluene Nutrition 0.000 description 1
- 229940095259 butylated hydroxytoluene Drugs 0.000 description 1
- 210000000038 chest Anatomy 0.000 description 1
- KYKAJFCTULSVSH-UHFFFAOYSA-N chloro(fluoro)methane Chemical compound F[C]Cl KYKAJFCTULSVSH-UHFFFAOYSA-N 0.000 description 1
- 235000012000 cholesterol Nutrition 0.000 description 1
- 150000001840 cholesterol esters Chemical class 0.000 description 1
- 239000000812 cholinergic antagonist Substances 0.000 description 1
- 229960005233 cineole Drugs 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 230000000052 comparative effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 239000003246 corticosteroid Substances 0.000 description 1
- 229960001334 corticosteroids Drugs 0.000 description 1
- 238000002788 crimping Methods 0.000 description 1
- 239000000625 cyclamic acid and its Na and Ca salt Substances 0.000 description 1
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 230000006378 damage Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 230000001066 destructive effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- ZBCBWPMODOFKDW-UHFFFAOYSA-N diethanolamine Chemical compound OCCNCCO ZBCBWPMODOFKDW-UHFFFAOYSA-N 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 235000019325 ethyl cellulose Nutrition 0.000 description 1
- 229920001249 ethyl cellulose Polymers 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- UKACHOXRXFQJFN-UHFFFAOYSA-N heptafluoropropane Chemical compound FC(F)C(F)(F)C(F)(F)F UKACHOXRXFQJFN-UHFFFAOYSA-N 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 238000002664 inhalation therapy Methods 0.000 description 1
- 239000001282 iso-butane Substances 0.000 description 1
- 239000000832 lactitol Substances 0.000 description 1
- 235000010448 lactitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-JVCRWLNRSA-N lactitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-JVCRWLNRSA-N 0.000 description 1
- 229960003451 lactitol Drugs 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000003199 leukotriene receptor blocking agent Substances 0.000 description 1
- 235000001510 limonene Nutrition 0.000 description 1
- 229940087305 limonene Drugs 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 229940071648 metered dose inhaler Drugs 0.000 description 1
- NJTGANWAUPEOAX-UHFFFAOYSA-N molport-023-220-454 Chemical compound OCC(O)CO.OCC(O)CO NJTGANWAUPEOAX-UHFFFAOYSA-N 0.000 description 1
- IJDNQMDRQITEOD-UHFFFAOYSA-N n-butane Chemical compound CCCC IJDNQMDRQITEOD-UHFFFAOYSA-N 0.000 description 1
- 238000002663 nebulization Methods 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 229940038384 octadecane Drugs 0.000 description 1
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- ALDITMKAAPLVJK-UHFFFAOYSA-N prop-1-ene;hydrate Chemical group O.CC=C ALDITMKAAPLVJK-UHFFFAOYSA-N 0.000 description 1
- 239000001294 propane Substances 0.000 description 1
- QMYDVDBERNLWKB-UHFFFAOYSA-N propane-1,2-diol;hydrate Chemical compound O.CC(O)CO QMYDVDBERNLWKB-UHFFFAOYSA-N 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- HNJBEVLQSNELDL-UHFFFAOYSA-N pyrrolidin-2-one Chemical compound O=C1CCCN1 HNJBEVLQSNELDL-UHFFFAOYSA-N 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 239000000600 sorbitol Substances 0.000 description 1
- 235000010356 sorbitol Nutrition 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000006068 taste-masking agent Substances 0.000 description 1
- 150000003505 terpenes Chemical class 0.000 description 1
- 235000007586 terpenes Nutrition 0.000 description 1
- BSYVTEYKTMYBMK-UHFFFAOYSA-N tetrahydrofurfuryl alcohol Chemical compound OCC1CCCO1 BSYVTEYKTMYBMK-UHFFFAOYSA-N 0.000 description 1
- 231100001274 therapeutic index Toxicity 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 229940042585 tocopherol acetate Drugs 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 150000005691 triesters Chemical class 0.000 description 1
- 239000005526 vasoconstrictor agent Substances 0.000 description 1
- 229920002554 vinyl polymer Polymers 0.000 description 1
- 239000003039 volatile agent Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/12—Aerosols; Foams
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU43827/01A AU774250B2 (en) | 1997-06-13 | 2001-05-11 | Pharmaceutical aerosol composition |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9712434A GB2326334A (en) | 1997-06-13 | 1997-06-13 | Pharmaceutical aerosol compositions |
| GB9712434 | 1997-06-13 | ||
| PCT/EP1998/003533 WO1998056349A1 (en) | 1997-06-13 | 1998-06-10 | Pharmaceutical aerosol composition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU43827/01A Division AU774250B2 (en) | 1997-06-13 | 2001-05-11 | Pharmaceutical aerosol composition |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| AU8626298A AU8626298A (en) | 1998-12-30 |
| AU729966B2 true AU729966B2 (en) | 2001-02-15 |
Family
ID=10814179
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU86262/98A Expired AU729966B2 (en) | 1997-06-13 | 1998-06-10 | Pharmaceutical aerosol composition |
Country Status (44)
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9616237D0 (en) | 1996-08-01 | 1996-09-11 | Norton Healthcare Ltd | Aerosol formulations |
| US20010031244A1 (en) | 1997-06-13 | 2001-10-18 | Chiesi Farmaceutici S.P.A. | Pharmaceutical aerosol composition |
| DZ2947A1 (fr) | 1998-11-25 | 2004-03-15 | Chiesi Farma Spa | Inhalateur à compteur de dose sous pression. |
| IT1303788B1 (it) * | 1998-11-25 | 2001-02-23 | Chiesi Farma Spa | Formulazioni di aerosol medicinali. |
| IT1313553B1 (it) | 1999-07-23 | 2002-09-09 | Chiesi Farma Spa | Formulazioni ottimizzate costituite da soluzioni di steroidi dasomministrare per inalazione. |
| EP1143930B8 (en) | 1999-09-11 | 2008-03-19 | Glaxo Group Limited | Pharmaceutical formulation of fluticasone propionate |
| EP1523976A3 (en) * | 1999-11-23 | 2005-06-22 | Glaxo Group Limited | Pharmaceutical formulations of salmeterol |
| AU2206801A (en) * | 1999-12-24 | 2001-07-09 | Alan Leslie Cripps | Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate |
| IT1317846B1 (it) * | 2000-02-22 | 2003-07-15 | Chiesi Farma Spa | Formulazioni contenenti un farmaco anticolinergico per il trattamentodella broncopneumopatia cronica ostruttiva. |
| IT1318514B1 (it) * | 2000-05-12 | 2003-08-27 | Chiesi Farma Spa | Formulazioni contenenti un farmaco glucocorticosteroide per iltrattamento di patologie broncopolmonari. |
| SK286694B6 (sk) * | 2000-05-22 | 2009-03-05 | Chiesi Farmaceutici S.P.A. | Aerosólový farmaceutický prostriedok |
| WO2002072067A2 (en) * | 2001-03-12 | 2002-09-19 | Glaxo Group Limited | Pharmaceutical aerosol formulation |
| TR200401980T4 (tr) | 2001-07-02 | 2004-09-21 | Chiesi Farmaceutici S.P.A. | Aerosol olarak uygulama için en uygun hale getirilmiş tobramisin formülasyonu |
| PT3384931T (pt) | 2002-03-01 | 2019-09-26 | Chiesi Farm Spa | Formulaçâo superfina de formoterol |
| EP1340503A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Solution aerosol formulation containing esters of 3, 17-dihydroxy oestratriene derivates for pulmonary delivery |
| EP1340492A1 (en) * | 2002-03-01 | 2003-09-03 | CHIESI FARMACEUTICI S.p.A. | Aerosol formulations for pulmonary administration of medicaments having systemic effects |
| DE10214263A1 (de) * | 2002-03-28 | 2003-10-16 | Boehringer Ingelheim Pharma | HFA-Suspensionsformulierungen enthaltend ein Anticholinergikum |
| ES2275778T3 (es) * | 2002-06-06 | 2007-06-16 | Chiesi Farmaceutici S.P.A. | Solubilizacion de farmacos en propulsores de hfa mediante emulsiones. |
| AU2003293528A1 (en) * | 2003-02-04 | 2004-09-06 | Chrysalis Technologies Incorporated | Perfluorocarbon and hydrofluorocarbon formulations and methods of making and using same |
| EP1915985A1 (en) * | 2003-03-20 | 2008-04-30 | Boehringer Ingelheim Pharmaceuticals Inc. | Formulation for a Metered Dose Inhaler Using Hydro-Fluoro-Alkanes as Propellants |
| US7914770B2 (en) * | 2003-03-20 | 2011-03-29 | Boehringer Ingelheim Pharmaceuticals, Inc. | Formulation for a metered dose inhaler using hydro-fluoro-alkanes as propellants |
| SE0303179D0 (sv) * | 2003-11-26 | 2003-11-26 | Astrazeneca Ab | Novel compounds |
| EP1595531A1 (en) | 2004-05-13 | 2005-11-16 | CHIESI FARMACEUTICI S.p.A. | Stable pharmaceutical solution formulations for pressurized metered dose inhalers |
| KR101297061B1 (ko) | 2004-07-02 | 2013-08-19 | 베링거 인겔하임 인터내셔날 게엠베하 | 추진제로서 ｔｇ ２２７ ｅａ 또는 ｔｇ １３４ ａ를함유하는 에어로졸 현탁액 제형 |
| DE102006017320A1 (de) | 2006-04-11 | 2007-10-18 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Aerosolsuspensionsformulierungen mit TG 227 ea oder TG 134 a als Treibmittel |
| GB0621707D0 (en) * | 2006-10-31 | 2006-12-13 | Univ London Pharmacy | Formulations for delivery via pressurised metered dose inhalers |
| GB0712454D0 (en) | 2007-06-27 | 2007-08-08 | Generics Uk Ltd | Pharmaceutical compositions |
| CA2704639A1 (en) * | 2007-11-07 | 2009-05-14 | Astrazeneca Ab | Dry powder formulations comprising ascorbic acid derivates |
| CN105854136A (zh) * | 2010-09-06 | 2016-08-17 | 奇斯药制品公司 | 计量剂量吸入器和使用该计量剂量吸入器的方法 |
| JP5409594B2 (ja) * | 2010-12-22 | 2014-02-05 | キエシ・フアルマチエウテイチ・ソチエタ・ペル・アチオニ | 加圧式定量吸入器のための安定な製薬学的溶液製剤 |
| WO2013127738A1 (de) | 2012-02-28 | 2013-09-06 | Boehringer Ingelheim International Gmbh | Neue treibgashaltige tiotropium-formulierung |
| RU2504402C1 (ru) * | 2012-11-20 | 2014-01-20 | Шолекс Девелопмент Гмбх | Ингаляционный состав в форме аэрозоля для лечения бронхиальной астмы и хронической обструктивной болезни легких |
| GB201402513D0 (en) | 2014-02-13 | 2014-04-02 | Cardiff Scintigraphics Ltd | Pressurised metered dose inhalers and method of manufacture |
| US20170189329A1 (en) | 2014-07-29 | 2017-07-06 | 3M Innovative Properties Company | Method of preparing a pharmaceutical composition |
| EP3436115B1 (en) | 2016-03-31 | 2021-07-28 | Chiesi Farmaceutici S.p.A. | Aerosol inhalation device |
| WO2018051131A1 (en) * | 2016-09-19 | 2018-03-22 | Mexichem Fluor S.A. De C.V. | Pharmaceutical composition |
| WO2025039045A1 (en) * | 2023-08-23 | 2025-02-27 | Inhaler Supplies Pty Ltd | Inhalable formulation for volatile actives |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1992008446A1 (en) * | 1990-11-09 | 1992-05-29 | Glaxo Group Limited | Aerosol medicaments |
| EP0372777B1 (en) * | 1988-12-06 | 1993-01-07 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| DE4123668A1 (de) * | 1991-07-17 | 1993-01-21 | Rovema Gmbh | Verfahren und vorrichtung zur zufuehrung von folienmaterial zu einer intermittierend arbeitenden schlauchbeutelmaschine |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0240484B1 (de) † | 1986-03-10 | 1992-01-15 | Kurt Dr. Burghart | Pharmazeutische Zubereitung sowie Verfahren zur Herstellung derselben |
| US4863720A (en) † | 1986-03-10 | 1989-09-05 | Walter Burghart | Pharmaceutical preparation and methods for its production |
| US4899874A (en) † | 1988-04-26 | 1990-02-13 | Rehrig-Pacific Company, Inc. | Stackable low depth bottle case |
| US5225183A (en) † | 1988-12-06 | 1993-07-06 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| DE3905726A1 (de) * | 1989-02-24 | 1990-08-30 | Hoechst Ag | Druckgaspackung und treibmittel fuer aerosole |
| ES2064160T3 (es) † | 1990-10-18 | 1995-01-16 | Minnesota Mining & Mfg | Formulacion de aerosol que comprende 17,21-dipropionato de beclometasona. |
| EP0504112A3 (en) * | 1991-03-14 | 1993-04-21 | Ciba-Geigy Ag | Pharmaceutical aerosol formulations |
| ATE339952T1 (de) † | 1991-06-10 | 2006-10-15 | Schering Corp | Fluorchlorkohlenwasserstofffreie aerosolformulierungen |
| US5474759A (en) * | 1991-06-10 | 1995-12-12 | Schering Corporation | Non-chlorofluorocarbon aerosol formulations |
| DE4123663A1 (de) * | 1991-07-17 | 1993-01-21 | Schwabe Willmar Gmbh & Co | Aerosol-zubereitung und verwendung eines treibmittels dafuer |
| JP3280974B2 (ja) * | 1991-12-12 | 2002-05-13 | グラクソ、グループ、リミテッド | 医 薬 |
| JP3908269B2 (ja) * | 1991-12-18 | 2007-04-25 | スリーエム カンパニー | 懸濁エアゾール製剤 |
| NZ259192A (en) * | 1992-12-09 | 1997-05-26 | Boehringer Ingelheim Pharma | Aerosol medicament comprising water-sensitive or solvent-sensitive active agent, hfc propellant stabilised by addition of (in)organic acid |
| US5502076A (en) * | 1994-03-08 | 1996-03-26 | Hoffmann-La Roche Inc. | Dispersing agents for use with hydrofluoroalkane propellants |
| US5508023A (en) * | 1994-04-11 | 1996-04-16 | The Center For Innovative Technology | Pharmaceutically acceptable agents for solubilizing, wetting, emulsifying, or lubricating in metered dose inhaler formulations which use HFC-227 propellant |
| US5534242A (en) † | 1994-05-02 | 1996-07-09 | Henry; Richard A. | Lidocaine-vasoconstrictor aerosol preparation |
| EP0759744B1 (en) † | 1994-05-13 | 2001-10-17 | Aradigm Corporation | Narcotic containing aerosol formulation |
| US5653961A (en) † | 1995-03-31 | 1997-08-05 | Minnesota Mining And Manufacturing Company | Butixocort aerosol formulations in hydrofluorocarbon propellant |
| US5635161A (en) † | 1995-06-07 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing vegetable oils |
| GB9517998D0 (en) † | 1995-09-04 | 1995-11-08 | Bioglan Lab Ltd | Compositions and device for their administration |
| WO1998001147A1 (en) * | 1996-07-08 | 1998-01-15 | Rhone-Poulenc Rorer Limited | Medicinal cyclosporin-a aerosol solution formulation |
| IES80485B2 (en) † | 1996-12-04 | 1998-08-12 | Bioglan Ireland R & D Ltd | Pharmaceutical compositions and devices for their administration |
| WO1998034595A1 (de) † | 1997-02-05 | 1998-08-13 | Jago Research Ag | Medizinische aerosolformulierungen |
-
1997
- 1997-06-13 GB GB9712434A patent/GB2326334A/en not_active Withdrawn
- 1997-07-28 IT IT97MI001798A patent/IT1293803B1/it active IP Right Grant
-
1998
- 1998-06-10 AT AT98937474T patent/ATE222751T1/de active
- 1998-06-10 EA EA199900201A patent/EA001259B1/ru not_active IP Right Cessation
- 1998-06-10 KR KR1019997001274A patent/KR100546239B1/ko not_active Expired - Lifetime
- 1998-06-10 BR BRPI9805993-9A patent/BR9805993B1/pt active IP Right Grant
- 1998-06-10 PT PT98937474T patent/PT920302E/pt unknown
- 1998-06-10 TR TR1999/00288T patent/TR199900288T1/xx unknown
- 1998-06-10 WO PCT/EP1998/003533 patent/WO1998056349A1/en not_active Ceased
- 1998-06-10 EP EP02007496A patent/EP1219293A3/en not_active Withdrawn
- 1998-06-10 PL PL98331531A patent/PL193721B1/pl unknown
- 1998-06-10 NZ NZ334149A patent/NZ334149A/xx not_active IP Right Cessation
- 1998-06-10 IL IL12848498A patent/IL128484A/en not_active IP Right Cessation
- 1998-06-10 SK SK176-99A patent/SK284430B6/sk not_active IP Right Cessation
- 1998-06-10 DE DE69807420T patent/DE69807420T3/de not_active Expired - Lifetime
- 1998-06-10 EP EP98937474A patent/EP0920302B2/en not_active Expired - Lifetime
- 1998-06-10 ME MEP-2008-440A patent/ME00333B/me unknown
- 1998-06-10 CZ CZ1999462A patent/CZ295521B6/cs not_active IP Right Cessation
- 1998-06-10 SI SI9830245T patent/SI0920302T2/sl unknown
- 1998-06-10 EE EEP199900055A patent/EE03664B1/xx unknown
- 1998-06-10 HU HU0001339A patent/HU228487B1/hu unknown
- 1998-06-10 AU AU86262/98A patent/AU729966B2/en not_active Expired
- 1998-06-10 ES ES98937474T patent/ES2182351T5/es not_active Expired - Lifetime
- 1998-06-10 RS YUP-69/99A patent/RS51274B/sr unknown
- 1998-06-10 DK DK98937474T patent/DK0920302T4/da active
- 1998-06-10 CA CA002263445A patent/CA2263445C/en not_active Expired - Lifetime
- 1998-06-10 CN CNB988008300A patent/CN1138532C/zh not_active Expired - Lifetime
- 1998-06-10 GE GEAP19984709A patent/GEP20012462B/en unknown
- 1998-06-10 ME MEP-440/08A patent/MEP44008A/xx unknown
- 1998-06-10 JP JP50162299A patent/JP4380802B2/ja not_active Expired - Lifetime
- 1998-06-10 ID IDW990051A patent/ID21491A/id unknown
- 1998-06-12 MY MYPI98002641A patent/MY119074A/en unknown
- 1998-06-12 AR ARP980102805A patent/AR012977A1/es not_active Application Discontinuation
- 1998-06-12 HR HR980317A patent/HRP980317B1/xx not_active IP Right Cessation
- 1998-06-12 MA MA25113A patent/MA26507A1/fr unknown
- 1998-06-12 CO CO98033837A patent/CO4940408A1/es unknown
- 1998-06-12 ZA ZA985136A patent/ZA985136B/xx unknown
- 1998-06-12 TN TNTNSN98087A patent/TNSN98087A1/fr unknown
- 1998-06-13 DZ DZ980126A patent/DZ2516A1/xx active
- 1998-06-18 IN IN1604DE1998 patent/IN189317B/en unknown
- 1998-07-08 TW TW087111036A patent/TW555570B/zh not_active IP Right Cessation
- 1998-10-06 UA UA99020906A patent/UA70289C2/uk unknown
- 1998-11-25 SA SA98190821A patent/SA98190821B1/ar unknown
-
1999
- 1999-02-09 NO NO19990594A patent/NO327775B1/no not_active IP Right Cessation
- 1999-02-11 IS IS4974A patent/IS2435B/is unknown
- 1999-03-01 BG BG103221A patent/BG63906B1/bg unknown
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0372777B1 (en) * | 1988-12-06 | 1993-01-07 | Riker Laboratories, Inc. | Medicinal aerosol formulations |
| WO1992008446A1 (en) * | 1990-11-09 | 1992-05-29 | Glaxo Group Limited | Aerosol medicaments |
| DE4123668A1 (de) * | 1991-07-17 | 1993-01-21 | Rovema Gmbh | Verfahren und vorrichtung zur zufuehrung von folienmaterial zu einer intermittierend arbeitenden schlauchbeutelmaschine |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU729966B2 (en) | Pharmaceutical aerosol composition | |
| US8420058B2 (en) | Pharmaceutical aerosol composition | |
| CA2352483C (en) | Pharmaceutical aerosol composition containing hfa 227 and hfa 134a | |
| AU774250B2 (en) | Pharmaceutical aerosol composition |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |